Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
Indaptus Therapeutics Stock Performance
Shares of NASDAQ INDP opened at $0.83 on Monday. Indaptus Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.10. The firm has a market cap of $11.65 million, a price-to-earnings ratio of -0.48 and a beta of 1.60. The stock’s 50-day simple moving average is $0.86 and its 200-day simple moving average is $1.10.
Wall Street Analyst Weigh In
Separately, Maxim Group dropped their target price on Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
Featured Stories
- Five stocks we like better than Indaptus Therapeutics
- What is a Death Cross in Stocks?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- What is a Dividend King?
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
